Altshuler Shaham’s UroGen Pharma URGN Stock Holding History

Altshuler Shaham’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44K	Buy	+39	New	+$1.06K	﹤0.01%	453
2022 Q3	–	Sell	-22,801	Closed	-$187K	–	536
2022 Q2	$187K	Hold	22,801	–	–	﹤0.01%	133
2022 Q1	$199K	Sell	22,801 -19,700	-46%	-$154K	﹤0.01%	219
2021 Q4	$404K	Hold	42,501	–	–	﹤0.01%	206
2021 Q3	$719K	Hold	42,501	–	–	0.01%	186
2021 Q2	$649K	Hold	42,501	–	–	﹤0.01%	190
2021 Q1	$828K	Buy	42,501 +19,000	+81%	+$403K	0.01%	109
2020 Q4	$423K	Hold	23,501	–	–	0.01%	116
2020 Q3	$453K	Hold	23,501	–	–	0.01%	127
2020 Q2	$614K	Hold	23,501	–	–	0.02%	90
2020 Q1	$419K	Sell	23,501 -2,671	-10%	-$72.2K	0.02%	100
2019 Q4	$873K	Hold	26,172	–	–	0.02%	77
2019 Q3	$620K	Buy	26,172 +280	+1%	+$9.15K	0.02%	86
2019 Q2	$931K	Buy	25,892 +1,194	+5%	+$44K	0.04%	82
2019 Q1	$912K	Hold	24,698	–	–	0.04%	87
2018 Q4	$1.06M	Buy	+24,698	New	+$1.11M	0.05%	82

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Altshuler Shaham's URGN Position: Q2 2026 in Review

Altshuler Shaham opened a new position in UroGen Pharma (URGN) in Q2 2026: 39 shares worth $1.44K. The stake represents ﹤0.01% of the portfolio and ranks #453 among its holdings. This is a return to the name: Altshuler Shaham previously reported a position in URGN as recently as Q2 2022.

Altshuler Shaham first reported a position in URGN in Q4 2018 and has held it in 16 quarters since. The position peaked at $1.06M in Q4 2018. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Altshuler Shaham held 39 shares of UroGen Pharma worth $1.44K as of Q2 2026.
UroGen Pharma was a new Altshuler Shaham position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Altshuler Shaham's portfolio in Q2 2026, its #453 holding.
Altshuler Shaham first reported a position in UroGen Pharma in Q4 2018 and has held it in 16 quarters since.
Altshuler Shaham's UroGen Pharma position peaked at $1.06M in Q4 2018.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Altshuler Shaham's 13F filing for Q2 2026, filed 12 Aug 2026.